AdAlta Limited

AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The Company's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. It is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. It co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.